Release and bioactivity of bone morphogenetic protein-2 are affected by scaffold binding techniques in vitro and in vivo.

A low dose of 1μg rhBMP-2 was immobilised by four different functionalising techniques on recently developed poly(l-lactide)-co-(ε-caprolactone) [(poly(LLA-co-CL)] scaffolds. It was either (i) physisorbed on unmodified scaffolds [PHY], (ii) physisorbed onto scaffolds modified with nanodiamond particles [nDP-PHY], (iii) covalently linked onto nDPs that were used to modify the scaffolds [nDP-COV] or (iv) encapsulated in microspheres distributed on the scaffolds [MICS]. Release kinetics of BMP-2 from the different scaffolds was quantified using targeted mass spectrometry for up to 70days. PHY scaffolds had an initial burst of release while MICS showed a gradual and sustained increase in release. In contrast, NDP-PHY and nDP-COV scaffolds showed no significant release, although nDP-PHY scaffolds maintained bioactivity of BMP-2. Human mesenchymal stem cells cultured in vitro showed upregulated BMP-2 and osteocalcin gene expression at both week 1 and week 3 in the MICS and nDP-PHY scaffold groups. These groups also demonstrated the highest BMP-2 extracellular protein levels as assessed by ELISA, and mineralization confirmed by Alizarin red. Cells grown on the PHY scaffolds in vitro expressed collagen type 1 alpha 2 early but the scaffold could not sustain rhBMP-2 release to express mineralization. After 4weeks post-implantation using a rat mandible critical-sized defect model, micro-CT and Masson trichrome results showed accelerated bone regeneration in the PHY, nDP-PHY and MICS groups. The results demonstrate that PHY scaffolds may not be desirable for clinical use, since similar osteogenic potential was not seen under both in vitro and in vivo conditions, in contrast to nDP-PHY and MICS groups, where continuous low doses of BMP-2 induced satisfactory bone regeneration in both conditions. The nDP-PHY scaffolds used here in critical-sized bone defects for the first time appear to have promise compared to growth factors adsorbed onto a polymer alone and the short distance effect prevents adverse systemic side effects.

[1]  Andrés J. García,et al.  Extracellular matrix-mimetic adhesive biomaterials for bone repair. , 2011, Journal of biomedical materials research. Part A.

[2]  王靖,et al.  Bone regeneration using cell-mediated responsive degradable PEG-based scaffolds incorporating with rhBMP-2 , 2012 .

[3]  I. Noh,et al.  Effects of recombinant human bone morphogenic protein-2 and human bone marrow-derived stromal cells on in vivo bone regeneration of chitosan-poly(ethylene oxide) hydrogel. , 2013, Journal of biomedical materials research. Part A.

[4]  A. Finne‐Wistrand,et al.  Comparison of Short-Run Cell Seeding Methods for Poly(L-Lactide-co-1,5-Dioxepan-2-one) Scaffold Intended for Bone Tissue Engineering , 2011, The International journal of artificial organs.

[5]  W. Sebald,et al.  Sustained Release Carriers Used to Delivery Bone Morphogenetic Proteins in the Bone Healing Process , 2008, Anatomia, histologia, embryologia.

[6]  M. Shokrgozar,et al.  Nanodiamonds for surface engineering of orthopedic implants: Enhanced biocompatibility in human osteosarcoma cell culture , 2013 .

[7]  Dong-Woo Cho,et al.  In vitro and in vivo evaluation of bone formation using solid freeform fabrication-based bone morphogenic protein-2 releasing PCL/PLGA scaffolds , 2014, Biomedical materials.

[8]  G. Niebur,et al.  Osteogenic differentiation of mesenchymal stem cells is regulated by osteocyte and osteoblast cells in a simplified bone niche. , 2012, European cells & materials.

[9]  Glenn D Prestwich,et al.  Hyaluronic acid-based hydrogels functionalized with heparin that support controlled release of bioactive BMP-2. , 2012, Biomaterials.

[10]  Yang Sun,et al.  Biological effects of functionalizing copolymer scaffolds with nanodiamond particles. , 2013, Tissue engineering. Part A.

[11]  C. Huck,et al.  Nanocrystalline diamond--an excellent platform for life science applications. , 2007, Journal of nanoscience and nanotechnology.

[12]  Andreas Ebner,et al.  The role of oxygen termination of nanocrystalline diamond on immobilisation of BMP-2 and subsequent bone formation. , 2008, Biomaterials.

[13]  R. Reis,et al.  Controlled release strategies for bone, cartilage, and osteochondral engineering--Part II: challenges on the evolution from single to multiple bioactive factor delivery. , 2013, Tissue engineering. Part B, Reviews.

[14]  E. Ōsawa,et al.  Multi-protein Delivery by Nanodiamonds Promotes Bone Formation , 2013, Journal of dental research.

[15]  A. Albertsson,et al.  Biocompatibility of Polyester Scaffolds with Fibroblasts and Osteoblast-like Cells for Bone Tissue Engineering , 2010 .

[16]  A. Krueger,et al.  Functionality is Key: Recent Progress in the Surface Modification of Nanodiamond , 2012 .

[17]  S. Gygi,et al.  Absolute quantification of proteins and phosphoproteins from cell lysates by tandem MS , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  M. Ozawa,et al.  Unusually tight aggregation in detonation nanodiamond: Identification and disintegration , 2005 .

[19]  Eyal Zussman,et al.  Slow-release human recombinant bone morphogenetic protein-2 embedded within electrospun scaffolds for regeneration of bone defect: in vitro and in vivo evaluation. , 2011, Tissue engineering. Part A.

[20]  D. Mooney,et al.  Growth factor delivery-based tissue engineering: general approaches and a review of recent developments , 2011, Journal of The Royal Society Interface.

[21]  S. Venkatraman,et al.  Release Retardation of Model Protein on Polyelectrolyte-Coated PLGA Nano- and Microparticles , 2014, PloS one.

[22]  J. Jansen,et al.  Non-glycosylated BMP-2 can induce ectopic bone formation at lower concentrations compared to glycosylated BMP-2. , 2012, Journal of controlled release : official journal of the Controlled Release Society.

[23]  A. Albertsson,et al.  Effect of endothelial cells on bone regeneration using poly(L-lactide-co-1,5-dioxepan-2-one) scaffolds. , 2011, Journal of biomedical materials research. Part A.

[24]  X. Zhu,et al.  Polymer microspheres for controlled drug release. , 2004, International journal of pharmaceutics.

[25]  Qin Liu,et al.  Improvement in the delivery system of bone morphogenetic protein-2: a new approach to promote bone formation , 2012, Biomedical materials.

[26]  Mark C Simmonds,et al.  Safety and Effectiveness of Recombinant Human Bone Morphogenetic Protein-2 for Spinal Fusion , 2013, Annals of Internal Medicine.

[27]  Yubo Fan,et al.  Controlled release of BSA by microsphere-incorporated PLGA scaffolds under cyclic loading , 2011 .

[28]  E. Hunziker,et al.  The effect of a slow mode of BMP-2 delivery on the inflammatory response provoked by bone-defect-filling polymeric scaffolds. , 2010, Biomaterials.

[29]  Herbert Riechelmann,et al.  Sheep as a Large Animal Model for Middle and Inner Ear Implantable Hearing Devices: A Feasibility Study in Cadavers , 2012, Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology.

[30]  U. Lerner,et al.  Osteoclast progenitor cells present in significant amounts in mouse calvarial osteoblast isolations and osteoclastogenesis increased by BMP-2. , 2013, Bone.

[31]  A. Priezzhev,et al.  Adsorption of human blood plasma on nanodiamond and its influence on activated partial thromboplastin time , 2013 .

[32]  A. Krueger New Carbon Materials: Biological Applications of Functionalized Nanodiamond Materials , 2008 .

[33]  H. Yoshikawa,et al.  Bone Morphogenetic Proteins in Bone Stimulate Osteoclasts and Osteoblasts During Bone Development , 2006, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[34]  E. Hunziker,et al.  BMP-2 liberated from biomimetic implant coatings induces and sustains direct ossification in an ectopic rat model. , 2005, Bone.

[35]  C. Susin,et al.  Effect of rhBMP-2 dose on bone formation/maturation in a rat critical-size calvarial defect model. , 2014, Journal of clinical periodontology.

[36]  Daocheng Wu,et al.  Preparation and property of a novel bone graft composite consisting of rhBMP-2 loaded PLGA microspheres and calcium phosphate cement , 2008, Journal of materials science. Materials in medicine.

[37]  Ann-Christine Albertsson,et al.  A strategy for the covalent functionalization of resorbable polymers with heparin and osteoinductive growth factor. , 2008, Biomacromolecules.

[38]  A Wennerberg,et al.  Determining optimal surface roughness of TiO(2) blasted titanium implant material for attachment, proliferation and differentiation of cells derived from human mandibular alveolar bone. , 2001, Clinical oral implants research.

[39]  S. Glassman,et al.  Adverse Effects Associated With High-Dose Recombinant Human Bone Morphogenetic Protein-2 Use in Anterior Cervical Spine Fusion , 2006, Spine.

[40]  Stuart B Goodman,et al.  The sequential expression profiles of growth factors from osteoprogenitors [correction of osteroprogenitors] to osteoblasts in vitro. , 2007, Tissue engineering.

[41]  A. Albertsson,et al.  Osteogenic Differentiation by Rat Bone Marrow Stromal Cells on Customized Biodegradable Polymer Scaffolds , 2010 .

[42]  M C Sogayar,et al.  Bone Morphogenetic Proteins , 2014, Journal of dental research.

[43]  C. Vedeler,et al.  Discovery and initial verification of differentially abundant proteins between multiple sclerosis patients and controls using iTRAQ and SID-SRM. , 2013, Journal of proteomics.

[44]  Rami Mosheiff,et al.  Tissue engineering approaches for bone repair: concepts and evidence. , 2011, Injury.

[45]  Yasuhiko Tabata,et al.  Bone Regeneration Using a Bone Morphogenetic Protein-2 Saturated Slow-Release Gelatin Hydrogel Sheet: Evaluation in a Canine Orbital Floor Fracture Model , 2010, Annals of plastic surgery.

[46]  C. Huck,et al.  Strong binding of bioactive BMP-2 to nanocrystalline diamond by physisorption. , 2006, Biomaterials.

[47]  S. Hollister,et al.  Chemically-conjugated bone morphogenetic protein-2 on three-dimensional polycaprolactone scaffolds stimulates osteogenic activity in bone marrow stromal cells. , 2010, Tissue engineering. Part A.

[48]  Georg N Duda,et al.  Biomaterial delivery of morphogens to mimic the natural healing cascade in bone. , 2012, Advanced drug delivery reviews.

[49]  A. Liese,et al.  Novel immobilization routes for the covalent binding of an alcohol dehydrogenase from Rhodococcus ruber DSM 44541 , 2008 .

[50]  William V Giannobile,et al.  Nano-fibrous scaffold for controlled delivery of recombinant human PDGF-BB. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[51]  Y. Missirlis,et al.  Protein–material interactions: From micro-to-nano scale , 2008 .

[52]  Miss A.O. Penney (b) , 1974, The New Yale Book of Quotations.

[53]  S. Santavirta,et al.  Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures: A Prospective, Controlled, Randomized Study of Four Hundred and Fifty Patients , 2002, The Journal of bone and joint surgery. American volume.

[54]  H. Genant,et al.  Recombinant Human Bone Morphogenetic Protein-2 for Treatment of Open Tibial Fractures , 2010 .

[55]  E. Hunziker,et al.  Osseointegration: the slow delivery of BMP-2 enhances osteoinductivity. , 2012, Bone.

[56]  S. Bhang,et al.  Long-term delivery enhances in vivo osteogenic efficacy of bone morphogenetic protein-2 compared to short-term delivery. , 2008, Biochemical and biophysical research communications.

[57]  A. Albertsson,et al.  In vitro and in vivo degradation profile of aliphatic polyesters subjected to electron beam sterilization. , 2011, Acta biomaterialia.

[58]  Yury Gogotsi,et al.  Adsorption of drugs on nanodiamond: toward development of a drug delivery platform. , 2013, Molecular pharmaceutics.

[59]  Michael J Yaszemski,et al.  Retention of in vitro and in vivo BMP-2 bioactivities in sustained delivery vehicles for bone tissue engineering. , 2008, Biomaterials.

[60]  Erin L. Hsu,et al.  A comparative evaluation of factors influencing osteoinductivity among scaffolds designed for bone regeneration. , 2013, Tissue engineering. Part A.

[61]  T. Kirsch,et al.  BMP‐2 antagonists emerge from alterations in the low‐affinity binding epitope for receptor BMPR‐II , 2000, The EMBO journal.